Pre-Analytical Stability of Serum Biomarkers for Neurological Disease Investigated
|
By LabMedica International staff writers Posted on 01 Apr 2022 |

Blood-based biomarkers are gaining increasing attention in the clinical field of neurological diseases, as they could contribute to accurate monitoring and prediction of disease and treatment outcomes.
Neurofilament-light (NfL), glial fibrillary acidic protein (GFAP) and contactin-1 (CNTN1) are blood-based biomarkers that could contribute to monitoring and prediction of disease and treatment outcomes in neurological diseases. Pre-analytical sample handling might affect results, which could be disease-dependent.
Neurochemists at the Vrije Universiteit Amsterdam (Amsterdam, The Netherlands) tested common handling variations in serum of volunteers as well as in a defined group of patients with multiple sclerosis (pwMS). Sample sets from five pwMS and five volunteers at the outpatient clinic were collected. The team investigated the effect of the following variables: collection tube type, delayed centrifugation, centrifugation temperature, delayed storage after centrifugation and freeze-thawing.
Prior to the NfL and GFAP analyses, serum samples were rapidly thawed, vortexed and centrifuged at 10,000×g for 10 minutes at room temperature. NfL and GFAP were simultaneously analyzed by a Simoa Single Molecule Array platform using the HDx analyzer with the Neurology 2-Plex B multiplex assay (Quanterix, Billerica, MA, USA). Prior to CNTN1 analysis, in a second set of aliquots, serum samples were thawed, vortexed and centrifuged at 10,000×g for 10 minutes at room temperature. The samples were analyzed using the Human contactin-1 Magnetic Luminex Assay (R&D systems, Minneapolis, MN, USA) on a Bio-Plex 200 system (Bio-Rad Laboratories, Hercules, CA, USA).
The scientists reported that for most pre-analytical variables, serum NfL and CNTN1 levels remained unaffected. In the total group, NfL levels increased (121%) after 6 hours of delay at 2–8 °C until centrifugation, while no significant changes were observed after 24 hours delay at room temperature (RT). In pwMS specifically, CNTN1 levels increased from additional freeze-thaw cycles number 2 to 4 (111%–141%), whereas volunteer levels remained stable. GFAP showed good stability for all pre-analytical variables. Serum NfL levels were relatively higher in pwMS (median 6.9 pg/mL, compared to volunteers (4.8 pg/mL). The same was found for serum GFAP levels (pwMS: 60.5 pg/mL; volunteers: 52.1 pg/mL). Serum CNTN1 levels were relatively lower in pwMS (8,103 pg/mL) compared to volunteers (10,671 pg/mL).
The authors concluded that overall, the serum biomarkers tested were relatively unaffected by variations in sample handling. For serum NfL, they recommend storage at RT before centrifugation at 2–8 °C up to 6 hours or at RT up to 24 hours. For serum CNTN1, they advise a maximum of two freeze-thaw cycles. Their results confirm and expand on recently launched consensus standardized operating procedures. The study was published in the journal Clinical Chemistry and Laboratory Medicine.
Related Links:
Vrije Universiteit Amsterdam
Quanterix
R&D systems
Bio-Rad Laboratories
Latest Clinical Chem. News
- Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
- Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
- Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
- Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
- Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
- Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
- Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
- Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
Channels
Molecular Diagnostics
view channel
RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis
Alzheimer’s disease affects an estimated 55 million people worldwide and remains difficult to diagnose at an early stage. Diagnostic workups can be complicated by symptom overlap with other conditions,... Read more
AI Reasoning Model Generates Diagnostic Leads for Unresolved Rare Disease Cases
Rare genetic diseases often leave families without definitive answers, even after genome sequencing and expert review. As scientific evidence evolves and clinical data remain fragmented across systems,... Read more
Point-of-Care Molecular Test Detects Group A Strep in Minutes
Group A Streptococcus is a leading bacterial cause of acute pharyngitis and a common reason for outpatient visits, accounting for millions of healthcare encounters each year. Because symptoms of bacterial... Read more
Genetic Testing and Surveillance Cuts Costs and Improves Survival in Li-Fraumeni Syndrome
Inherited cancer predisposition syndromes such as Li-Fraumeni syndrome (LFS) can lead to diverse, early-onset tumors and require intensive, lifelong surveillance. Balancing timely identification with sustainable... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreMicrobiology
view channel
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more








